Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Leukemia

Free Subscription Articles published in Cancer Retrieve available abstracts of 59 articles: HTML format

Single Articles

May 2025
1. KANTARJIAN H, Jain N, Litzow MR, Luger SM, et al
   The evolving therapeutic revolution in adult acute lymphoblastic leukemia.
   Cancer. 2025;131:e35872.
   PubMed     Abstract available
   
   
   
2. ATALLAH E, Lipton JH
   Has the time for treatment-free remission in Philadelphia chromosome-positive acute lymphoblastic leukemia arrived?
   Cancer. 2025;131:e35880.
   PubMed    
   
   
   
3. WINESTONE LE, Yang J, Banerjee T, Sangaramoorthy M, et al
   Impact of neighborhood archetypes on overall mortality among young patients with acute leukemia in California.
   Cancer. 2025;131:e35863.
   PubMed     Abstract available
   
   
   April 2025
4. KANTARJIAN H, Zhai Y, Oehler VG, Jamy O, et al
   Olverembatinib in chronic myeloid leukemia-Review of historical development, current status, and future research.
   Cancer. 2025;131:e35832.
   PubMed     Abstract available
   
   
   
5. THAKUR RK, Wang ES
   Top advances of the year: Acute myeloid leukemia.
   Cancer. 2025;131:e35834.
   PubMed    
   
   
   
6. GOULART H, Kantarjian H, Borthakur G, Daver N, et al
   Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial.
   Cancer. 2025;131:e35840.
   PubMed     Abstract available
   
   
   
7. PETERS DT, Zeidner JF
   A second look at the status quo for secondary acute myeloid leukemia after hypomethylating agents.
   Cancer. 2025;131:e35838.
   PubMed    
   
   
   
8. LEBER B, Ruiz MT, Elgendy H, Pettersson F, et al
   Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia.
   Cancer. 2025;131:e35845.
   PubMed     Abstract available
   
   
   
9. KHOURI MR, Wang B, Pearson LK, Gillis-Smith AJ, et al
   Characteristics and clinical outcomes of patients with myeloid malignancies and cohesin mutations.
   Cancer. 2025;131:e35846.
   PubMed     Abstract available
   
   
   
10. SENAPATI J, Kadia TM, Daver NG, DiNardo CD, et al
    Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges.
    Cancer. 2025;131:e35806.
    PubMed     Abstract available
    
    
    
11. PAPAYANNIDIS C, Petracci E, Zappasodi P, Fracchiolla N, et al
    INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia.
    Cancer. 2025;131:e35820.
    PubMed     Abstract available
    
    
    
12. NANNI J, Azzali I, Papayannidis C, Mule A, et al
    Upfront intensive treatment analysis of the Italian Cohort Study on FLT3-mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real-life setting.
    Cancer. 2025;131:e35824.
    PubMed     Abstract available
    
    
    March 2025
13. 
    Erratum to "Incorporation of alemtuzumab into frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study".
    Cancer. 2025;131:e35803.
    PubMed    
    
    
    
14. BAZINET A, Bataller A, Kadia T, Daver N, et al
    A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia.
    Cancer. 2025;131:e35813.
    PubMed     Abstract available
    
    
    
15. KUGLER E, Kantarjian H, Jabbour E, Khaire N, et al
    Treatment-free remission in nontransplanted patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Cancer. 2025;131:e35773.
    PubMed     Abstract available
    
    
    
16. BROWN JC, Ma C, Shi Q, Saltz LB, et al
    The association of physical activity with survival in colon cancer versus a matched general population: Data from Cancer and Leukemia Group B 89803 and 80702 (Alliance).
    Cancer. 2025;131:e35727.
    PubMed     Abstract available
    
    
    February 2025
17. LUSKIN MR, Yin J, Lozanski G, Curran E, et al
    Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study.
    Cancer. 2025;131:e35750.
    PubMed     Abstract available
    
    
    
18. GYAN E, Minden MD, Kubo K, Rambaldi A, et al
    Maintenance therapy with the FMS-like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS-like tyrosine kinase 3-internal tandem duplication acute myeloid leukemia: A phase 2 study.
    Cancer. 2025;131:e35746.
    PubMed     Abstract available
    
    
    
19. ESKAZAN AE
    Patient-reported outcomes in Chinese patients with chronic myeloid leukemia receiving olverembatinib: Quality of life matters!
    Cancer. 2025;131:e35737.
    PubMed    
    
    
    January 2025
20. WANG L, Chen Y, Zang M, Zhou J, et al
    Molecular measurable residual disease before transplantation independently predicts survival and relapse risk in adult lysine methyltransferase 2a-rearranged acute myeloid leukemia.
    Cancer. 2025;131:e35717.
    PubMed     Abstract available
    
    
    
21. LLORET-MADRID P, Boluda B, Martinez-Lopez J, Bergua J, et al
    Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study.
    Cancer. 2025;131:e35696.
    PubMed     Abstract available
    
    
    
22. SASAKI K
    Favorable transplantation outcome of patients with de novo chronic myeloid leukemia in blast phase (lymphoid and myeloid).
    Cancer. 2025;131:e35704.
    PubMed    
    
    
    
23. ARGUELLO-TOMAS M, Mozas P, Albiol N, Lopez-Esteban M, et al
    Risk scores predicting disease progression in early-stage chronic lymphocytic leukemia: Comparative analysis and usefulness of IGHV subset #2 to improve their accuracy.
    Cancer. 2025;131:e35552.
    PubMed     Abstract available
    
    
    November 2024
24. YU L, Li W, Xu N, Liu X, et al
    Patient-reported outcomes in adults with tyrosine kinase inhibitor-resistant chronic myeloid leukemia receiving olverembatinib therapy.
    Cancer. 2024 Nov 26. doi: 10.1002/cncr.35652.
    PubMed     Abstract available
    
    
    
25. JEN WY, Marvin-Peek J, Kantarjian HM, Alvarado Y, et al
    Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia.
    Cancer. 2024 Nov 25. doi: 10.1002/cncr.35662.
    PubMed     Abstract available
    
    
    
26. ZHANG C, Gu R, Wang H, Zhou C, et al
    Risk stratification in the clinical application of minimal residual disease assessment in acute myeloid leukemia.
    Cancer. 2024 Nov 10. doi: 10.1002/cncr.35641.
    PubMed     Abstract available
    
    
    
27. OKADA Y, Tachi N, Shimazu Y, Murata M, et al
    Comparing de novo chronic myeloid leukemia in blastic phase with Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation.
    Cancer. 2024 Nov 4. doi: 10.1002/cncr.35627.
    PubMed     Abstract available
    
    
    
28. NIERENGARTEN MB
    Blinatumomab approved as consolidation therapy for MRD-negative B-cell precursor acute lymphoblastic leukemia.
    Cancer. 2024;130:3622.
    PubMed    
    
    
    
29. NIERENGARTEN MB
    New predictive model for treatment failure in chronic myeloid leukemia.
    Cancer. 2024;130:3621.
    PubMed    
    
    
    
30. HOANG TT, Rathod RA, Rosales O, Castellanos MI, et al
    Residential proximity to oil and gas developments and childhood cancer survival.
    Cancer. 2024;130:3724-3733.
    PubMed     Abstract available
    
    
    October 2024
31. RODRIGUEZ-ARBOLI E, Rodriguez-Veiga R, Soria-Saldise E, Bergua JM, et al
    A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX.
    Cancer. 2024 Oct 30. doi: 10.1002/cncr.35618.
    PubMed     Abstract available
    
    
    
32. KONDO T, Matsuki E, Takaku T, Watanabe N, et al
    Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
    Cancer. 2024 Oct 30. doi: 10.1002/cncr.35611.
    PubMed     Abstract available
    
    
    
33. NIERENGARTEN MB
    Durable efficacy with fixed-duration BTKi and venetoclax for CLL.
    Cancer. 2024;130:3237.
    PubMed    
    
    
    September 2024
34. LI Z, Zhang X, Zhao Y, Lu L, et al
    Imatinib dose reduction after major molecular response in chronic-phase chronic myeloid leukemia.
    Cancer. 2024 Sep 21. doi: 10.1002/cncr.35565.
    PubMed     Abstract available
    
    
    August 2024
35. ZHANG X, Wang Y, Tian X, Sun L, et al
    Delineation of features, responses, outcomes, and prognostic factors in pediatric PDGFRB-positive acute lymphoblastic leukemia patients: A retrospective multicenter study.
    Cancer. 2024 Aug 13. doi: 10.1002/cncr.35481.
    PubMed     Abstract available
    
    
    
36. KANTARJIAN HM, Boissel N, Papayannidis C, Luskin MR, et al
    Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions.
    Cancer. 2024 Aug 2. doi: 10.1002/cncr.35505.
    PubMed     Abstract available
    
    
    July 2024
37. JEN WY, Konopleva M, Pemmaraju N
    Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature.
    Cancer. 2024;130:2260-2271.
    PubMed     Abstract available
    
    
    June 2024
38. LABRADOR J, Martinez-Cuadron D, Boluda B, Serrano J, et al
    Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry.
    Cancer. 2024 Jun 19. doi: 10.1002/cncr.35431.
    PubMed     Abstract available
    
    
    May 2024
39. SENAPATI J, Kantarjian HM, Bazinet A, Reville P, et al
    Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation.
    Cancer. 2024 May 29. doi: 10.1002/cncr.35388.
    PubMed     Abstract available
    
    
    
40. HADDAD FG, Sasaki K, Nasr L, Short NJ, et al
    Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase.
    Cancer. 2024 May 28. doi: 10.1002/cncr.35384.
    PubMed     Abstract available
    
    
    
41. BAZARBACHI AH, Labopin M, Raiola AM, Blaise D, et al
    Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Tran
    Cancer. 2024 May 17. doi: 10.1002/cncr.35365.
    PubMed     Abstract available
    
    
    April 2024
42. JABBOUR E, Haddad FG, Sasaki K, Carter BZ, et al
    Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
    Cancer. 2024 Apr 9. doi: 10.1002/cncr.35317.
    PubMed     Abstract available
    
    
    
43. LOKE J, Labopin M, Craddock C, Socie G, et al
    Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party
    Cancer. 2024 Apr 6. doi: 10.1002/cncr.35308.
    PubMed     Abstract available
    
    
    
44. WANG X, Zhang B, Zhang Q, Zhou H, et al
    Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia.
    Cancer. 2024 Apr 5. doi: 10.1002/cncr.35316.
    PubMed     Abstract available
    
    
    March 2024
45. DUFFY C, Hunger SP, Bhakta N, Denburg AE, et al
    Curing pediatric cancer: A global view. Examples from acute lymphoblastic leukemia.
    Cancer. 2024 Mar 29. doi: 10.1002/cncr.35290.
    PubMed    
    
    
    
46. HUANG R, He H, Xu X, Lin X, et al
    Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.
    Cancer. 2024 Mar 12. doi: 10.1002/cncr.35278.
    PubMed     Abstract available
    
    
    
47. ROSENBERG SM, McCue S, He J, Lafky JM, et al
    Alliance A151945: Accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017.
    Cancer. 2024;130:750-769.
    PubMed     Abstract available
    
    
    February 2024
48. DINH A, Savoy JM, Kontoyiannis DP, Takahashi K, et al
    Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Cancer. 2024 Feb 10. doi: 10.1002/cncr.35251.
    PubMed     Abstract available
    
    
    
49. GUAN F, Yang L, Chen Y, Shi J, et al
    Comparison of long-term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia-positive acute lymphoblastic leukemia: A multicenter retrospective study.
    Cancer. 2024 Feb 5. doi: 10.1002/cncr.35232.
    PubMed     Abstract available
    
    
    January 2024
50. SEDETA E, Jemal A, Nisotel L, Sung H, et al
    Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt.
    Cancer. 2024 Jan 20. doi: 10.1002/cncr.35214.
    PubMed     Abstract available
    
    
    December 2023
51. PALANDRI F, Palumbo GA, Benevolo G, Iurlo A, et al
    Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
    Cancer. 2023 Dec 28. doi: 10.1002/cncr.35156.
    PubMed     Abstract available
    
    
    November 2023
52. YANG X, Yang L, Luo A, Liu S, et al
    IKZF3 polymorphisms contribute to the increased risk of acute lymphoblastic leukemia in children.
    Cancer. 2023 Nov 29. doi: 10.1002/cncr.35129.
    PubMed     Abstract available
    
    
    
53. RUIZ J, Li Y, Cao L, Huang YV, et al
    Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemia.
    Cancer. 2023 Nov 20. doi: 10.1002/cncr.35109.
    PubMed     Abstract available
    
    
    
54. NIERENGARTEN MB
    New potential therapy for relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Cancer. 2023;129:3356.
    PubMed    
    
    
    October 2023
55. PULLARKAT V, Chen LS, Palmer J, Zhang J, et al
    A phase 1 trial of 8-chloro-adenosine in relapsed/refractory acute myeloid leukemia: An evaluation of safety and pharmacokinetics.
    Cancer. 2023 Oct 28. doi: 10.1002/cncr.35077.
    PubMed     Abstract available
    
    
    
56. GUPTA DG, Varma N, Abdulkadir SA, Sreedharanunni S, et al
    A surrogate molecular approach for the detection of Philadelphia chromosome-like B-acute lymphoblastic leukemia.
    Cancer. 2023 Oct 11. doi: 10.1002/cncr.35051.
    PubMed     Abstract available
    
    
    
57. EFFICACE F, Cottone F, Yanez B, Kota V, et al
    Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia.
    Cancer. 2023 Oct 6. doi: 10.1002/cncr.35021.
    PubMed     Abstract available
    
    
    September 2023
58. SASAKI K, Haddad FG, Short NJ, Jain N, et al
    Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019.
    Cancer. 2023 Sep 28. doi: 10.1002/cncr.35038.
    PubMed     Abstract available
    
    
    
59. GIEBEL S, Labopin M, Salmenniemi U, Socie G, et al
    Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors. A study from the Acute Leukemia Working Party of the
    Cancer. 2023 Sep 1. doi: 10.1002/cncr.35004.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.